Inflammatix Expands Leadership Team
Inflammatix, a leader in molecular diagnostics, has made significant strides by adding three industry veterans to its executive leadership team. This strategic expansion is aimed at spearheading the commercialization of the company's flagship product, the TriVerity™ Test. The newly appointed executives include Dr. Sam Ajizian as Chief Medical Officer, Jamie Lewis as Chief Commercial Officer, and Laura Spencer Garth as General Counsel.
Meet the New Executives
Dr. Sam Ajizian – Chief Medical Officer
Dr. Ajizian brings nearly a decade of seasoned experience from Medtronic, where he served as chief medical officer in Acute Care and Monitoring. His leadership capabilities shone through as he managed a team dedicated to clinical research and patient management, serving over 115 million patients globally. Dr. Ajizian will play a crucial role in overseeing the medical aspects of the TriVerity Test launch, including education initiatives for healthcare professionals.
Jamie Lewis – Chief Commercial Officer
With an impressive background in commercial strategy, Jamie Lewis is set to lead the commercial organization for TriVerity. Her past successes include operationalizing growth strategies at Outset Medical, contributing to their IPO success and fostering innovation in surgical robotics at Intuitive Surgical. Now, she aims to leverage her extensive industry knowledge to build a robust commercial framework for Inflammatix.
Laura Spencer Garth – General Counsel
Laura Spencer Garth joins the team with a wealth of legal expertise in the medical device sector. Formerly general counsel for Stereotaxis and Veran Medical Technologies, she is well-versed in corporate legal matters and compliance, which will be invaluable in steering Inflammatix's legal and regulatory strategies as it moves toward further growth and commercialization.
The TriVerity™ Test Explained
The TriVerity™ Test is a groundbreaking diagnostic tool that operates on the innovative Myrna™ Instrument, which is designed to analyze blood for rapid immune response readings. Utilizing advanced algorithms, this test aims to facilitate better diagnostic decisions concerning infection and patient management during emergency medical scenarios. The goal is to enable clinicians to administer appropriate antimicrobial therapy and other necessary interventions swiftly.
This test highlights Inflammatix's commitment to enhancing patient care by providing critical information regarding the presence of infection and the potential for severe illness. By leveraging machine learning technology, TriVerity delivers insights that are otherwise difficult to obtain quickly, allowing healthcare professionals to make informed decisions right at the point of care.
The Future of Inflammatix
As Inflammatix prepares for the upcoming launch of TriVerity, the involvement of Dr. Ajizian, Ms. Lewis, and Ms. Spencer Garth signals a pivotal enhancement in capabilities to meet regulatory standards and market demands. Each of these leaders brings a unique skill set and a shared commitment to driving transformative change in the healthcare landscape.
With a focus on precision medicine, Inflammatix is on track to improve diagnostic accuracy and overall patient outcomes through its rapidly advancing technology. The company’s approach not only aims to provide immediate insights but also seeks to address widespread healthcare challenges, thus positioning itself as a critical player in the diagnostics arena.
About Inflammatix
Located in Sunnyvale, California, Inflammatix, Inc. is committed to developing cutting-edge diagnostic solutions that interpret a patient’s immune response, aiming to tackle significant public health issues. With the support of notable venture capital firms, Inflammatix employs a sample-to-answer isothermal platform to deliver high-precision medical diagnostics. The company strives to bring innovative tests to market that enhance healthcare delivery and improve patient management.
Frequently Asked Questions
What is the TriVerity™ Test?
The TriVerity™ Test is a diagnostic blood test that measures immune responses to infections, designed for use in emergency departments.
Who are the new executives at Inflammatix?
The new executives include Dr. Sam Ajizian (Chief Medical Officer), Jamie Lewis (Chief Commercial Officer), and Laura Spencer Garth (General Counsel).
What is the role of the Myrna™ Instrument?
The Myrna™ Instrument is a proprietary analyzer used to perform the TriVerity Test, providing rapid results in less than 30 minutes.
How does the TriVerity Test help physicians?
The test assists physicians in making timely decisions regarding treatment options and patient admissions based on infection severity.
Where is Inflammatix located?
Inflammatix is headquartered in Sunnyvale, California, USA.
